Effect of rolipram, a phosphodiesterase IV inhibitor, on allergic footpad swelling using various adjuvants in mice

Scandinavian Journal of Immunology

Volumn 62, Issue 4, 2005, Pages 378-384

  Yamaki, K ^a   Alam, A H M K ^b   Hossain, A ^b   Taneda, S ^c   Yanagisawa, R ^d   Takano, H ^d   Yoshino, S ^a  

^a KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF RAJSHAHI   (Bangladesh)

^c Air Pollutants Health Effects Research Team   (Japan)

^d NATIONAL INSTITUTE FOR ENVIRONMENTAL STUDIES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FREUND ADJUVANT; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 4; OVALBUMIN; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM;

ALLERGIC REACTION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; FOOT PAD; IMMUNOGLOBULIN PRODUCTION; LEG EDEMA; MALE; MICROEMULSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TH2 CELL;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELLS, CULTURED; EDEMA; FOOT; HYPERSENSITIVITY; MALE; MICE; MICE, INBRED DBA; OVALBUMIN; PHOSPHODIESTERASE INHIBITORS; ROLIPRAM; SPLEEN; TH1 CELLS; TH2 CELLS;

EID: 27644442711     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2005.01662.x     Document Type: Article

References (32)

1. Mossmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348-57.
2. Mossmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-73.
3. Dickensheets HL, Venkataraman C, Schindler U, Donnelly RP. Interferons inhibit activation of STAT6 by interleukin 4 in human monocytes by inducing SOCS-1 gene expression. Proc Nad Acad Sci USA 1999;96:10800-5.
4. van Roon JA, van Roy JL, Duits A, Lafeber FP, Bijilsma JW. Proinflammatory cytokine production and cartilage damage due to rheumatoid synovial T helper-1 activation is inhibited by interleukin-4. Ann Rheum Dis 1995;54:836-40.
5. Yin Z, Braun J, Neure L et al. Crucial role of interleukin-10/ interleukin-12 balance in the regulation of the type 2 T helper cytokine response in reactive arthritis. Arthritis Rheum 1997;40:1788-97.
6. + T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995;16:34-8.
7. Sigidin YA, Loukina GV, Skurkovich B, Skurkovich S. Randomized, double-blind trial of anti-interferon-γ antibodies in rheumatoid arthritis. Scand J Rheumatol 2001;30:203-7.
8. Oliverstein R, Taha R, Minshall EM, Hamid QA. IL-4 and IL-5 mRNA expression in induced sputum of asthmatic subjects: comparison with bronchial wash. J Allergy Clin Immunol 1999;103:238-45.
9. Corry DB, Folkesson HG, Warnock ML et al. Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hypersensitivity. J Exp Med 1996;183:109-17.
10. Kammer GM. The adenylate cyclase cAMP-protein kinase A pathway and regulation of the immune responses. Immunol Today 1998;9:222-9.
11. Munoz E, Zubiaga AM, Merrow M, Sauter NP, Huber BT. Cholera toxin discriminates between T helper 1 and 2 cells in T cell receptor-mediated activation: role of cAMP in T cell proliferation. J Exp Med 1990;172:95-103.
12. Novak TJ, Rothenberg EV. Cyclic AMP inhibits induction of interleukin-2 but not of interleukin-4 in T-cells. Proc Natl Acad Sci USA 1990;87:9353-7.
13. Betz M, Fox BS. Prostaglandin E2 inhibits production of Th-1 lymphokines but not of Th-2 lymphokines. J Immunol 1991;146: 108-13.
14. van der Poow-Kraan T, van Kooten C, Rensink I, Aarden L. Interleukin (IL)-4 production by human T cells: differential regulation of IL-4 vs. IL-2 production. Eur J Immunol 1992;22: 1237-41.
15. Abbas N, Zou LP, Pelidou SH, Winblad B, Zhu J. Protective effect of rolipram in experimental autoimmune neuritis: protection is associated with down-regulation of IFN-γ and inflammatory chemokines as well as up-regulation of IL-4 in peripheral nervous system. Autoimmunity 2000;32:93-9.
16. Kanehiro A, Ikemura T, Makela MJ et al. Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge. Am J Respir Crit Care Med 2001;163:173-84.
17. Griswold DE, Webb EF, Badger AM et al. SB207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor α and interleukin-4 production in vivo. J Pharmacol Exp Ther 1998;287:705-11.
18. Yamaki K, Li X, Uchida H et al. Effects of the phosphodiesterase IV inhibitor rolipram on Th1 and Th2 immune responses in mice. J Pharm Pharmacol 2004;56:877-82.
19. Yip CY, Karulin AY, Tary-Lehmann M et al. Adjuvant-guided type-1 and type-2 immunity: Infectious/noninfectious dichotomy defines the class of response. J Immunol 1999;162:3942-9.
20. Yoshino S, Sasatomi E, Mori Y, Sagai M. Oral administration of lipopolysaccharide exacerbates collagen-induced arthritis in mice. J Immunol 1999;163:3417-22.
21. Yoshino S, Murata Y, Ohsawa M. Successful induction of adjuvant arthritis in mice by treatment with a monoclonal antibody against IL-4. J Immunol 1998;161:6904-8.
22. Dombrowicz D, Flamand V, Miyajima I, Ravetch JV, Galli SJ, Kinet J-P. Absense of FcεRIα chain results in upregulation of FCγRIII-dependent mast cell degranulation and anaphylaxis. Evidence of competition between FcεRI and FcγRIII for limiting amounts of FcR β and γ chains. J Clin Invest 1997;99:915-25.
23. Hirayama N, Hirano T, Kohler G, Kurata A, Okumura K, Ovary Z. Biological activities of antitrinitrophenyl and antidinitrophenyl mouse monoclonal antibodies. Proc Nad Acad Sci USA 1982;79:613-5.
24. Sugimoto M, Kojima A, Yaginuma K, Egashira Y. Cell-mediated and humoral immunity in mice: cross reaction between lysozyme and S-carboxymethylated lysozyme studied by a modified footpad test. Jpn J Med Sci Biol 1975;28:23-35.
25. Underwood DC, Matthews JK, Osborn RR, Bochinowicz S, Torphy TJ. The influence of endogenous catecholamines on the inhibitory effects of rolipram against early- and late-phase response to antigen in the guinea pig. J Pharmacol Exp Ther 1997;280:210-9.
26. Banner KH, Moriggi E, Da Ros B, Schioppacassi G, Semeraro C, Page CP. The effect of selective phosphodiesterase 3 and 4 isoenzyme inhibitors and established anti-asthma drugs on inflammatory cell activation. Br J Pharmacol 1996;119:1255-61.
27. Shichijo M, Inagaki N, Nakai N et al. The effects of anti-asthma drugs on mediator release from cultured human mast cells. Clin Exp Allergy 1998;28:1228-36.
28. Dinter H, Tse J, Halks-Miller M et al. The type IV phosphodiesterase specific inhibitor mesopram inhibits experimental autoimmune encephalomyelitis in rodents. J Neuroimmunol 2000;108:136-46.
29. Navikas V, Matusevicius D, Soderstrom M, Pirskanen R, Fredrikson S, Link H. The phosphodiesterase i.v. inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN-γ and TNF-α mRNA expressing blood mononuclear cells in patients with multiple sclerosis. Clin Neuropharmacol 1998;21:236-44.
30. Ross SE, Williams RO, Mason LJ et al. Suppression of TNF-α expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram. J Immunol 1997;159:6253-9.
31. Heo Y, Lee WT, Lawrence DA. Differential effects of lead and cAMP on development and activities of Th1- and Th2-lymphocytes. Toxicol Sci 1998;43:172-85.
32. Coqueret O, Boichot E, Lagente V. Selective type IV phosphodiesterase inhibitors prevent IL-4-induced IgE production by human peripheral blood mononuclear cells. Clin Exp Allergy 1997;27:816-23.